单中心经验:乳腺癌质子治疗的计划与治疗推荐
基于约翰霍普金斯质子中心2019年11月至2022年2月收治的66例局限性乳腺癌患者数据,分析日常摆位位移、鲁棒性标准、每日影像及QA CT频率。推荐每日锥形束CT、3 mm摆位不确定度进行鲁棒性分析;有扩张器或植入物者治疗期间行2次QA CT,否则1次足够。
要点
- 推荐每日锥形束CT,因日常摆位变化大且3 mm摆位不确定度用于鲁棒性分析。
- 若无每日锥形束CT,则应使用更大的摆位不确定度。
- 有扩张器或植入物者治疗期间行2次QA CT,否则1次足够。
核心结论
- 推荐每日锥形束CT,因日常摆位变化大,鲁棒性分析采用3 mm摆位不确定度。
- 若无每日锥形束CT,则应使用更大的摆位不确定度。
- 有扩张器或植入物者治疗期间行2次QA CT,否则1次足够。
研究设计与样本
- 单中心经验性推荐,纳入2019年11月至2022年2月在约翰霍普金斯质子中心治疗的66例局限性乳腺癌患者。
- 患者包括19例保乳、25例未重建胸壁、22例胸壁加扩张器或植入物。
- 提取每日位移信息并通过控制图分析,记录自适应计划的重计划时间。
- 采用3 mm和5 mm摆位不确定度计算鲁棒性,比较QA CT鲁棒性评估与初始鲁棒性范围对乳腺/胸壁及淋巴结靶区覆盖。
主要发现
- 保乳、胸壁、扩张器/植入物患者中分别有16%、13%、41%进行了重计划。
- 仅扩张器或植入物患者需要2次自适应计划。
- 每日位移数据变异大,与计划自适应不相关。
- 无自适应计划患者QA CT的剂量体积直方图指标在鲁棒性范围内的频率高于有自适应计划者。
- 采用3 mm鲁棒性时,无自适应计划患者91%至100%的QA CT在鲁棒性范围内,而有自适应计划患者中腋窝、内乳淋巴结和锁骨上淋巴结的QA CT在鲁棒性范围内者为55%至60%。
关键数值与推荐
- 推荐每日锥形束CT。
- 鲁棒性分析采用3 mm摆位不确定度。
- 若无每日锥形束CT,则应使用更大的摆位不确定度。
- 有扩张器或植入物者治疗期间行2次QA CT。
- 无扩张器或植入物者治疗期间行1次QA CT。
临床怎么用
- 推荐每日锥形束CT成像。
- 鲁棒性分析采用3 mm摆位不确定度。
- 若无每日锥形束CT,则应使用更大的摆位不确定度。
- 有扩张器或植入物者治疗期间行2次QA CT。
- 无扩张器或植入物者治疗期间行1次QA CT。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Proton therapy use for breast cancer has grown due to advantages in coverage and potentially reduced late toxicities compared with conventional radiation therapy. We aimed to provide recommendations for robustness criteria, daily imaging, and quality assurance computed tomography (QA CT) frequency for these patients. METHODS AND MATERIALS: All patients treated for localized breast cancer at the Johns Hopkins Proton Center between November 2019 and February 2022 were eligible for inclusion. Daily shift information was extracted and examined through control charts. If an adaptive plan was used, the time to replan was recorded. Three and 5 mm setup uncertainty was used to calculate robustness. Robust evaluation of QA CTs was compared with initial robustness range for breast/chest wall and lymph node target coverage. RESULTS: Sixty-six patients were included: 19 with intact breast, 25 with non-reconstructed chest wall, and 22 with chest wall plus expanders or implants. Sixteen percent, 13%, and 41% of breast, chest wall, and expander/implant patients had a replan. Only patients with expanders or implants required 2 adaptive plans. Daily shift data showed large variation and did not correlate with plan adaptation. Patients without adaptive plans had QA CTs with dose-volume histogram metrics within robustness more frequently than those with adaptive plans. Using 3 mm robustness for patients who did not require an adaptive plan, 91% to 100% of patients had QA CTs within robustness, while 55% to 60% of patients with an adaptive plan had QA CTs within robustness for the axilla, internal mammary nodes, and supraclavicular nodes. Five millimeter setup uncertainty did not significantly improve this. CONCLUSIONS: We recommend using daily cone beam CT because of the large variation in daily setup with 3 mm setup uncertainty in robustness analysis. If daily cone beam CT imaging is not available, then larger setup uncertainty should be used. Two QA CTs should be conducted during treatment if the patient has expanders or implants; otherwise, one QA CT is sufficient.
引用
- Ger RB, Sheikh K, Gogineni E, et al. Planning and Treatment Recommendations for Breast Proton Therapy From a Single Center's Experience. Adv Radiat Oncol. 2022. PMID: 36213549. doi:10.1016/j.adro.2022.101069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。